Loading...
•
Dec 31, 2025
Amylyx Q4 2025 Earnings Report
Amylyx Q4 2025 Earnings Report
Key Takeaways
Amylyx reported a narrower net loss for the fourth quarter of 2025 compared to the prior year, driven by reduced operating expenses as the company shifts focus toward its pivotal Phase 3 LUCIDITY trial for avexitide. The company ended the year with a strong cash position of $317 million, providing a runway into 2028.
Recruitment for the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH) is complete.
Topline data for the LUCIDITY trial is anticipated in the third quarter of 2026.
Cash, cash equivalents, and short-term investments of $317 million are expected to fund operations into 2028.
Net loss per share improved to $0.30 in Q4 2025 compared to $0.55 in Q4 2024.
Forward Guidance
Amylyx is focused on executing its Phase 3 LUCIDITY trial and preparing for potential commercialization of avexitide in 2027.
Positive Outlook
- Cash runway expected to extend into 2028
- Topline data for Phase 3 LUCIDITY trial expected in Q3 2026
- Potential commercial launch of avexitide in 2027
- Biomarker data from Phase 1 LUMINA trial expected in H1 2026
- IND filing for AMX0318 targeted for 2027
Challenges Ahead
- Company currently generates zero product revenue
- Ongoing net losses as clinical trials progress
- Dependence on successful Phase 3 trial outcomes for avexitide
- Future commercialization remains subject to regulatory approval
- Macroeconomic and geopolitical uncertainties could impact operations
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...